Skip to main content

Our vision

Big Data is so 2016... Our aim is to provide Better Health Data. Rather than collecting data blindly, we believe it is more important to determine which data will be the most appropriate to improve patient care.

Our ambition is to develop clinically validated medical applications to help patients throughout their care pathway. 
We will seek CE marking and FDA clearance for our applications, as we are determined to meet the most stringent regulatory requirements.

The future of Medicine

We are convinced that medicine will evolve from a care approach centered around consultation to a personalized and continuous care, supported by new digital tools. From clinical research to daily care, the possibilities are astounding. 

Regarding public health, mobile applications and connected objects will help create new real-world databases for research within a precise and strictly controlled framework, in line with health authorities’ guidelines.

Patient-centricity

Patient is increasingly at the center of health systems. He can rely on new tools to access medical information, patient communities or services to better manage his care pathway. Building on these trends, Ad Scientiam is developing solutions making patients the main actors of their own health.

Confidentiality and Ethics

Working on health data is highly sensitive. By meeting strict ethical and confidentiality standards, Ad Scientiam offers reliable solutions to transform patient care

Ad Scientiam in the Press

Ad Scientiam a été citée à la télévision ce 3 juin dans une chronique dédiée à la Sclérose en Plaques

Sleep and Quality of Life Evaluation of Patients With Atopic Dermatitis Based on E-diary on a Smartphone Application and Actigraphy (ACTISLEEP)

Scientific article about Ad Scientiam solution in MS (DAMS)

created by Dr Mikaël COHEN - Neurologist Hôpital Pasteur, CHU Nice

We are presenting an application under development, dedicated to patients with Mutiple Sclerosis (MS). This solution aims at facilitating patient...